Rhodiola rosea has been extensively studied in Scandinavian countries and in Russia for over 35 years and is categorized as an adaptogen because of its ability to increase resistance to chemical, biological, and physical stressors. The adaptogenic properties of Rhodiola are attributed primarily to its ability to influence the levels and activity of neurotransmitters and the amino acids that mimic the effect of opiates, such as beta-endorphins, in the brain. Because it is an adaptogen, and not an opiate, Rhodiola has the potential to normalize neurotransmitters in the central nervous system without causing drowsiness or fatigue. It helps maintain normal levels of brain chemicals, but does not further affect them when they are already normal.

Studies have found improved mental performance in physicians on night shift who were supplemented with Rhodiola. And medical students given Rhodiola during exam periods reported improved concentration and performance, as well as enhanced well-being, improved sleep, and greater mood stability.

Studies from Russia suggest a positive role for Rhodiola in situations characterized by a decline in work performance, poor appetite, sleep disturbances, irritability, and fatigue.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.